Efficacy and Safety of Replacing Lenalidomide with Pomalidomide for Patients with Multiple Myeloma Refractory to a Lenalidomide-Containing Combination Regimen

Exp Hematol. 2022 Oct:114:54-60. doi: 10.1016/j.exphem.2022.07.303. Epub 2022 Aug 4.
No abstract available

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Bortezomib / therapeutic use
  • Dexamethasone / therapeutic use
  • Humans
  • Lenalidomide / adverse effects
  • Multiple Myeloma* / drug therapy
  • Thalidomide / adverse effects
  • Thalidomide / analogs & derivatives

Substances

  • Thalidomide
  • Bortezomib
  • Dexamethasone
  • pomalidomide
  • Lenalidomide